Onselex

2023

Oct. 06, 2023 ONX-1006 completed formal Good Laboratory Practice (GLP) toxicology test (over 30 tests and 5,000 page reports) achieving groundbreaking formal toxicology test results.
ONX-1006 achieved remarkable No Observed Adverse Effect Level (NOAEL) value with every GLP tests with rats and beagle dogs, including the pivotal ONX-1006 13 weeks Repeated IV (Once a Week, Total 13 Times) Dose Toxicity study, a 4-Week Recovery and Toxicokinetics study.
NOAEL data suggest that the ONX-1006 is very safe, non-toxic and would not cause any harmful treatment-emergent adverse events when it is administered to humans.

2022

Oct. 12, 2022 Professor Si-young Song, Distinguished Professor and Clinician at Yonsei University College of Medicine joined as a member of Onselex CAB.
Oct. 06, 2022 Professor Hosoon Choi, Chief at Hanyang University Medical Center joined as a member of Onselex CAB.
July 04, 2022 In the PK test of the ONX-1006 PANC-1 Xenograft mouse model, higher PTX was detected in the tumor tissue compared to the plasma.
Mar. 30, 2022 ONX-1006 anticancer drug, Beagle single IV administration toxicity GLP test: Confirmation of Beagle in the normal and safe state even after administration of 3 times the lethal dose of ONX-1006 (PTX 25mg/kg).
Mar. 03, 2022 Study for Anti-Tumor Effect of ONX-1006 on Tumor Growth Formed by AsPC-1 Carcinoma Cells, achived statically significant Efficacy results demonstrating highly effective nanomedicine, ONX-1006.

2021

Dec. 14, 2021 ONX-1006 GLP anticancer test (intravenous administration of rats): Confirmation of rats in a normal and safe state after administration of 50 times the lethal dose of the paclitaxel
Oct. 06, 2021 Completed development of ONX-2006 anticancer drug (Pills): stomach/colon cancer
Sep. 27, 2021 ONX-1006 AsPC-1 Pancreatic Cancer Cell Xenograft Model 3rd Outstanding Efficacy results achieved
Aug. 10, 2021 Initiated 3rd ONX-1006 Xenograft efficacy test (with Dt&C)
Mar. 30, 2021 Completed for entry into the national phase of the PCT international patent application

2020

Aug. 31, 2020 Signed a formal ONX-1006 Pre-clinical trial agreement
Aug. 27, 2020 Signed an agreement for ONX-1006 Efficacy animal trial
Aug. 25, 2020 Investment Capital: KRW 2.58 billion
July 13, 2020 Signed Nano Cancer Licensing Agreement with Onselex Pharma
July 10, 2020 Completed the mass production of the GLP ONX-1006 in kilogram scale
July 01, 2020 Signed a technology transfer agreement for Programmed Nanoparticle – Loaded Drug
Mar. 19, 2020 Founding of S. Korea company, Onselex Inc. (Founding capital: KRW 1.6 billion)

2018

주메뉴